New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 25, 2012
09:03 EDTSGENSeattle Genetics completes patients enrollment for clinical trial of ADCETRIS
Seattle Genetics and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company, announced the completion of patient enrollment in a phase III clinical trial of ADCETRIS, or brentuximab vedotin, for post-transplant Hodgkin lymphoma, or HL, patients. The phase III trial, also known as the AETHERA trial, is evaluating ADCETRIS versus placebo for the treatment of patients at high risk of residual Hodgkin lymphoma following autologous stem cell transplant. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL.
News For SGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
16:30 EDTSGENSeattle Genetics sees FY14 revenue from ADCETRIS $172M-$177M
Seattle Genetics anticipates that 2014 revenues from ADCETRIS net product sales in the U.S. and Canada will be higher than previously anticipated, and are now expected to be in the range of $172M-$177M. The company also anticipates that 2014 collaboration revenues will be higher than previously anticipated, and are now expected to be in the range of $64M-$68M.
16:30 EDTSGENSeattle Genetics reports Q3 EPS (13c), consensus (24c)
Subscribe for More Information
October 29, 2014
13:09 EDTSGENSeattle Genetics management to meet with Jefferies
Subscribe for More Information
October 27, 2014
10:52 EDTSGENSeattle Genetics, Aegerion CEOs accused of drug use in lawsuit, TheStreet says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use